Source Paper
Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Dietary creatine supplementation
Administer creatine supplementation to transgenic R6/2 mice through diet
Note: Treatment group receives creatine-supplemented diet; control group receives standard diet
View evidence from paper
“Dietary creatine supplementation significantly improved survival, slowed the development of brain atrophy”
Survival monitoring
Track and record survival rates in both creatine-supplemented and control R6/2 mice
Note: Primary outcome measure for neuroprotective effects
View evidence from paper
“Dietary creatine supplementation significantly improved survival”
Body weight assessment
Monitor and measure body weight in both treatment and control groups
Note: Body weight is a secondary outcome measure
View evidence from paper
“Body weight and motor performance on the rotarod test were significantly improved in creatine-supplemented R6/2 mice”
Rotarod motor performance testing
Assess motor performance using rotarod test in both creatine-supplemented and control mice
Note: Measures motor function and coordination
View evidence from paper
“Body weight and motor performance on the rotarod test were significantly improved in creatine-supplemented R6/2 mice”
Brain atrophy assessment
Evaluate development and progression of brain atrophy in both groups
Note: Measures neuroprotective effects on brain structure
View evidence from paper
“Dietary creatine supplementation significantly improved survival, slowed the development of brain atrophy”
Striatal neuron atrophy evaluation
Assess atrophy of striatal neurons in both treatment and control groups
Note: Measures regional neuroprotection
View evidence from paper
“delayed atrophy of striatal neurons and the formation of huntingtin-positive aggregates in R6/2 mice”
Huntingtin aggregate assessment
Evaluate formation of huntingtin-positive aggregates in both groups
Note: Measures pathological hallmark of Huntington's disease
View evidence from paper
“delayed atrophy of striatal neurons and the formation of huntingtin-positive aggregates in R6/2 mice”
Diabetes onset monitoring
Track and record onset of diabetes in both creatine-supplemented and control mice
Note: Secondary outcome measure; onset was markedly delayed in creatine group
View evidence from paper
“the onset of diabetes was markedly delayed”
Nuclear magnetic resonance spectroscopy analysis
Perform NMR spectroscopy to measure brain creatine concentrations and N-acetylaspartate concentrations
Note: Biochemical assessment of metabolic markers
View evidence from paper
“Nuclear magnetic resonance spectroscopy showed that creatine supplementation significantly increased brain creatine concentrations and delayed decreases in N-acetylaspartate concentrations”